Clinical trials
Lupus Erythematosus, Systemic trials in Romania
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
58 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Active, not recruiting | 12 |
| Recruiting | 10 |
| Terminated | 5 |
| Enrolling by invitation | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 5 |
| Bristol-Myers Squibb | 4 |
| EMD Serono Research & Development Institute, Inc. | 4 |
| Eli Lilly and Company | 4 |
| UCB Pharma | 4 |
| MedImmune LLC | 3 |
| Viatris Innovation GmbH | 3 |
| Biogen | 2 |
| GlaxoSmithKline | 2 |
| Human Genome Sciences Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lupus Erythematosus, Systemic | 58 |
| Autoimmune Diseases | 13 |
| Connective Tissue Diseases | 10 |
| Immune System Diseases | 8 |
| Lupus Erythematosus, Cutaneous | 5 |
| Lupus Erythematosus, Discoid | 5 |
| Lupus Nephritis | 5 |
| Arthritis, Rheumatoid | 2 |
| Nephritis | 2 |
| Skin and Connective Tissue Diseases | 2 |
Trials
Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.